pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
sniff results

“Keytruda”

152 total hits · 4 drugs · 0 companies · 0 diseases · 130 catalysts · 18 news

Drugs(4)

expand →
KEYTRUDA
KEYTRUDA · PEMBROLIZUMAB
Marketed
pembrolizumab
Keytruda · pembrolizumab
Merkel Cell Carcinoma
KEYTRUDA QLEX
KEYTRUDA QLEX · PEMBROLIZUMAB
Marketed
(berahyaluronidase alfa + pembrolizumab)
Keytruda Qlex · (berahyaluronidase alfa-pmph + pembrolizumab)
Muscle Invasive Bladder Cancer (MIBC)

🐶 Companies(0)

expand →
no companies matched

Catalysts(130)

expand →
view all 130 catalyst results →

News(18)

expand →
  • Merck's top dealmaker signals more M&A as Keytruda's patent cliff nears↗
    Merck CEO Robert Davis has been landing deals “with urgency” over the last few years in an effort to shore up the pipeline ahead of Keytruda’s upcoming patent cliff. But make no mistake: The compan…
    endpoints · 3d ago
  • Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again↗
    New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will ne…
    biospace · 3d ago
  • Akeso, Summit cancer drug confirms lung cancer survival benefit↗
    A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
    biopharma dive · 3d ago
  • BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer↗
    Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase…
    biospace · 9d ago
  • BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test↗
    Following Merck and Moderna’s phase 3 triumph with a Keytruda-paired personalized mRNA cancer vaccine, a similar shot from BioNTech and Genentech has faltered in a reminder of the approach’s strugg…
    fiercebiotech · 9d ago
  • Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future↗
    Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.
    biospace · 17d ago
  • Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact↗
    As the dust settles on phase 3 data that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: Can use of the vaccine b…
    fiercebiotech · 17d ago
  • Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal↗
    Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the…
    biospace · 18d ago
  • view all 18 news results →
    Apr 6, 2026
    approval
    5mo ago
    KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
    (berahyaluronidase alfa + pembrolizumab)
    →
    Apr 6, 2026
    approval
    5mo ago
    KEYTRUDA (PEMBROLIZUMAB) — FDA approval
    pembrolizumab
    →
    Feb 10, 2026
    approval
    7mo ago
    KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
    (berahyaluronidase alfa + pembrolizumab)
    →
    Feb 10, 2026
    approval
    7mo ago
    KEYTRUDA (PEMBROLIZUMAB) — FDA approval
    pembrolizumab
    →
    Nov 21, 2025
    approval
    10mo ago
    KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
    (berahyaluronidase alfa + pembrolizumab)
    →
    Nov 21, 2025
    approval
    10mo ago
    KEYTRUDA (PEMBROLIZUMAB) — FDA approval
    pembrolizumab
    →
    Sep 19, 2025
    approval
    12mo ago
    KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
    (berahyaluronidase alfa + pembrolizumab)
    →
    Sep 19, 2025
    approval
    12mo ago
    KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
    (berahyaluronidase alfa + pembrolizumab)
    →